68 related articles for article (PubMed ID: 9110144)
1. Interleukin-13 responsiveness and interleukin-13 receptor expression in non-Hodgkin's lymphoma and reactive lymph node B cells. Modulation by CD40 activation.
Billard C; Caput D; Vita N; Ferrara P; Orrico M; Gaulard P; Boumsell L; Bensussan A; Farcet JP
Eur Cytokine Netw; 1997 Mar; 8(1):19-27. PubMed ID: 9110144
[TBL] [Abstract][Full Text] [Related]
2. The human B cell response to IL-13 is dependent on cellular phenotype as well as mode of activation.
Ford D; Sheehan C; Girasole C; Priester R; Kouttab N; Tigges J; King TC; Luciani A; Morgan JW; Maizel AL
J Immunol; 1999 Sep; 163(6):3185-93. PubMed ID: 10477586
[TBL] [Abstract][Full Text] [Related]
3. Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors.
Voorzanger N; Touitou R; Garcia E; Delecluse HJ; Rousset F; Joab I; Favrot MC; Blay JY
Cancer Res; 1996 Dec; 56(23):5499-505. PubMed ID: 8968107
[TBL] [Abstract][Full Text] [Related]
4. A soluble form of IL-13 receptor alpha 1 promotes IgG2a and IgG2b production by murine germinal center B cells.
Poudrier J; Graber P; Herren S; Gretener D; Elson G; Berney C; Gauchat JF; Kosco-Vilbois MH
J Immunol; 1999 Aug; 163(3):1153-61. PubMed ID: 10415009
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effect of triptolide on lymph node metastasis in patients with non-Hodgkin lymphoma by regulating SDF-1/CXCR4 axis in vitro.
Zhang C; Cui GH; Liu F; Wu QL; Chen Y
Acta Pharmacol Sin; 2006 Nov; 27(11):1438-46. PubMed ID: 17049119
[TBL] [Abstract][Full Text] [Related]
6. Expression of a functional IL-13Ralpha1 by rat B cells.
Pierrot C; Beniguel L; Bègue A; Khalife J
Biochem Biophys Res Commun; 2001 Oct; 287(4):969-76. PubMed ID: 11573960
[TBL] [Abstract][Full Text] [Related]
7. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical expression of angiogenic cytokines and their receptors in reactive benign lymph nodes and non-Hodgkin lymphoma.
Ho CL; Sheu LF; Li CY
Ann Diagn Pathol; 2003 Feb; 7(1):1-8. PubMed ID: 12616467
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-2 receptor is functionally linked with in vitro activation of B cells isolated from non-Hodgkin's lymphomas.
Garraud O; LeGrand E; Eghbali H; Hoerni-Simon G; Hoerni B; Guillemain B
Diagn Clin Immunol; 1988; 5(6):417-20. PubMed ID: 3265363
[TBL] [Abstract][Full Text] [Related]
10. Leukotriene D4 enhances immunoglobulin production in CD40-activated human B lymphocytes.
Lamoureux J; Stankova J; Rola-Pleszczynski M
J Allergy Clin Immunol; 2006 Apr; 117(4):924-30. PubMed ID: 16630953
[TBL] [Abstract][Full Text] [Related]
11. Suppression of an IL-13 autocrine growth loop in a human Hodgkin/Reed-Sternberg tumor cell line by a novel IL-13 antagonist.
Oshima Y; Puri RK
Cell Immunol; 2001 Jul; 211(1):37-42. PubMed ID: 11585386
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis.
Alas S; Emmanouilides C; Bonavida B
Clin Cancer Res; 2001 Mar; 7(3):709-23. PubMed ID: 11297268
[TBL] [Abstract][Full Text] [Related]
13. Critical role of monocytes to support normal B cell and diffuse large B cell lymphoma survival and proliferation.
Mueller CG; Boix C; Kwan WH; Daussy C; Fournier E; Fridman WH; Molina TJ
J Leukoc Biol; 2007 Sep; 82(3):567-75. PubMed ID: 17575267
[TBL] [Abstract][Full Text] [Related]
14. Differential role for p38 mitogen-activated protein kinase in regulating CD40-induced gene expression in dendritic cells and B cells.
Aicher A; Shu GL; Magaletti D; Mulvania T; Pezzutto A; Craxton A; Clark EA
J Immunol; 1999 Dec; 163(11):5786-95. PubMed ID: 10570261
[TBL] [Abstract][Full Text] [Related]
15. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1.
Donaldson DD; Whitters MJ; Fitz LJ; Neben TY; Finnerty H; Henderson SL; O'Hara RM; Beier DR; Turner KJ; Wood CR; Collins M
J Immunol; 1998 Sep; 161(5):2317-24. PubMed ID: 9725226
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase II study of interleukin-12 in combination with rituximab in previously treated non-Hodgkin's lymphoma patients.
Ansell SM; Geyer SM; Maurer MJ; Kurtin PJ; Micallef IN; Stella P; Etzell P; Novak AJ; Erlichman C; Witzig TE
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6056-63. PubMed ID: 17062681
[TBL] [Abstract][Full Text] [Related]
17. IL-13R(alpha)2, a decoy receptor for IL-13 acts as an inhibitor of IL-4-dependent signal transduction in glioblastoma cells.
Rahaman SO; Sharma P; Harbor PC; Aman MJ; Vogelbaum MA; Haque SJ
Cancer Res; 2002 Feb; 62(4):1103-9. PubMed ID: 11861389
[TBL] [Abstract][Full Text] [Related]
18. Kinetic analysis of high affinity forms of interleukin (IL)-13 receptors: suppression of IL-13 binding by IL-2 receptor gamma chain.
Kuznetsov VA; Puri RK
Biophys J; 1999 Jul; 77(1):154-72. PubMed ID: 10388747
[TBL] [Abstract][Full Text] [Related]
19. Chromosome mapping and expression of the human interleukin-13 receptor.
Guo J; Apiou F; Mellerin MP; Lebeau B; Jacques Y; Minvielle S
Genomics; 1997 May; 42(1):141-5. PubMed ID: 9177784
[TBL] [Abstract][Full Text] [Related]
20. Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation.
Blanchard DA; Affredou MT; Vazquez A
J Immunol; 1997 Apr; 158(7):3054-61. PubMed ID: 9120257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
